Clinical trial · Observational
Italian Registry on the Prevalence of IDH1/IDH2 Mutations in Patients With Acute Myeloid Leukemia
NCT02986620CI-TRIAL-00055770completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a study where there are no interventions planned. Investigators will only collect data already in the patient's history and analyze it. Particularly, we are interested in molecular data from AML patients. This means that patients will follow their regular diagnostic and clinical practice. The analyses will be conducted according to the routine diagnostic and clinical practice as well and no additional blood withdrawal will be performed.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| AML, Adult | Adult Acute Myeloid Leukemia | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| IDH mutation test performed at diagnosis or relapse until January 31st, 2019. | Genetic | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- AML patients
- description
- Adult AML patients with the IDH mutation test performed at diagnosis or relapse until January 31st, 2019.
- interventionNames
- Genetic: IDH mutation test performed at diagnosis or relapse until January 31st, 2019.
Primary outcomes (2)
- measure
- Number of patients with the IDH mutations in AML at initial diagnosis.
- timeFrame
- At two years from study entry.
- measure
- Number of patients with the IDH mutations in AML at relapse.
- timeFrame
- At three years from study entry.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion criteria: * Signed written informed consent according to ICH/EU/GCP and national local laws (if applicable); * AML patients; * Age ≥18; * IDH mutation test performed at diagnosis or relapse until January 31st, 2019. Exclusion criteria: * AML M3 subtype according to the FAB classification;
References
Publications (0)
Data not yet available
No reference posted for this study.